Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia
In the register
The register attaches this trial to Dutasteride (Avodart / Zagallo) (GSK), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- GlaxoSmithKline
- Participants (registry)
- 917
- Start
- October 2010
- Primary completion
- February 2012
- Study completion
- February 2012
- Last registry update
- August 2018
- Countries
- Argentina, Chile, Japan, Mexico, Peru, Philippines, Russia, Taiwan, Thailand
Conditions studied: Androgenetic Alopecia
Interventions: 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride, 0.5mg dutasteride, Finasteride placebo, Dutasteride placebo
Other trials of Dutasteride (Avodart / Zagallo)
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
- NCT01004809Completed
AVODART® Alopecia Post-marketing Surveillance (PMS)
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.